Gland Pharma Limited has informed the Exchange about Investor Presentation
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported consolidated Q2 FY26 revenue of ₹14,869 Mn, up 6% year-on-year but down 1% sequentially. Adjusted EBITDA grew 13% YoY to ₹3,355 Mn with margin expanding to 23% from 21% a year ago, while PAT rose 12% YoY to ₹1,837 Mn. The base business (Gland) remained strong with 35% EBITDA margins and PAT up 7% YoY to ₹3,055 Mn. Subsidiary Cenexi continued to struggle, posting a €6 Mn EBITDA loss due to a planned shutdown at its Fontenay facility for upgrades, though the GMP certificate was renewed through end of CY2026. The company filed 6 ANDAs and received 5 approvals in the quarter, launched 7 new US molecules including Daptomycin-RTU, and is expanding GLP-1/pen/cartridge capacity from ~40 Mn to 140 Mn units. Net cash stood at ₹24,484 Mn with H1 operating cash flow of ₹5,933 Mn.
The strong base business performance and margin expansion should be viewed positively, but the QoQ decline in consolidated earnings and continued losses at Cenexi may weigh on short-term sentiment. Robust cash position and a deep pipeline (RTU bags addressing a ~$659 Mn US market opportunity, FY28 commercialization from co-development deals) support the long-term growth story.